Pralsetinib Capsules 普拉替尼胶囊

Pratinib is an oral targeted therapy drug, mainly used to treat malignant tumors such as advanced non-small cell lung cancer (NSCLC) and medullary thyroid carcinoma (MTC) with RET gene mutations or fusions. It blocks the tumor growth signaling pathway by selectively inhibiting abnormally activated RET proteins. It is a precision treatment method and must be used strictly in accordance with the doctor’s instructions.

Indications
Non-small cell lung cancer: Suitable for patients with locally advanced or metastatic disease who have been confirmed to have positive RET gene fusions.
Thyroid cancer: Including RET mutant medullary thyroid cancer and RET fusion-positive thyroid cancer that require systemic treatment.
Exploratory treatment of other RET mutation-related tumors (need clinical trial support).
Mechanism of action
RET gene abnormalities (mutations or fusions) lead to continuous activation of proteins and promote cancer cell proliferation.
Pratinib, as a highly selective RET inhibitor, can accurately bind to abnormal RET proteins and inhibit their activity, thereby blocking downstream signal transduction and delaying tumor progression.
Precautions for use
Gene testing required: RET mutation status must be confirmed by molecular testing before medication.
Side effect management: Common side effects include hypertension, fatigue, constipation, dry mouth, etc. In severe cases, interstitial lung disease or liver damage may occur, which requires regular monitoring.
Dosage adjustment: The dose is adjusted individually according to the patient’s tolerance. Do not increase or decrease or stop the drug on your own.
Contraindications and interactions: Avoid combined use with strong CYP3A4 inhibitors or inducers. It is contraindicated for pregnant women.
Clinical effects and research progress
Clinical trials have shown that the objective response rate (ORR) of patients with RET fusion-positive non-small cell lung cancer is about 65%-70%, and the median progression-free survival (PFS) is about 16-18 months.
Studies on thyroid cancer have shown that the disease control rate is significantly better than traditional chemotherapy.
Currently, its application in other RET-related tumors such as breast cancer and colorectal cancer is being explored.
Medical guidance
Pratinib is a prescription drug and needs to be used under the guidance of an oncologist. Genetic testing and systemic evaluation must be completed before treatment, and imaging and blood indicators must be reviewed regularly during treatment. If serious adverse reactions occur, seek medical attention immediately.